DDInter217 DDInter899
Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Bivalirudin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clove
Bivalirudin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaprozin
Bivalirudin {u} may lead to a major life threatening interaction when taken with {v} Reteplase
Bivalirudin {u} may lead to a major life threatening interaction when taken with {v} Lepirudin
Bivalirudin may cause a minor interaction that can limit clinical effects when taken with Clove
Bivalirudin may cause a moderate interaction that could exacerbate diseases when taken with Oxaprozin
Bivalirudin may lead to a major life threatening interaction when taken with Reteplase
Bivalirudin may lead to a major life threatening interaction when taken with Lepirudin